532 related articles for article (PubMed ID: 30871560)
21. Mechanisms and management of cough in interstitial lung disease.
Rasheed AZ; Metersky ML; Ghazal F
Expert Rev Respir Med; 2023 Dec; 17(12):1177-1190. PubMed ID: 38159067
[TBL] [Abstract][Full Text] [Related]
22. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Schmid U; Weber B; Sarr C; Freiwald M
BMC Pulm Med; 2021 Jul; 21(1):244. PubMed ID: 34289823
[TBL] [Abstract][Full Text] [Related]
23. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Schmid U; Weber B; Magnusson MO; Freiwald M
Respir Med; 2021; 180():106369. PubMed ID: 33798871
[TBL] [Abstract][Full Text] [Related]
24. Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey.
Olson A; Hartmann N; Patnaik P; Wallace L; Schlenker-Herceg R; Nasser M; Richeldi L; Hoffmann-Vold AM; Cottin V
Adv Ther; 2021 Feb; 38(2):854-867. PubMed ID: 33315170
[TBL] [Abstract][Full Text] [Related]
25. Health care costs and utilization of progressive fibrosing lung disease by underlying interstitial lung disease type.
Nili M; Steffens A; Anderson A; Brekke L; Grace Johnson M; Veeranki P; Olson AL
J Manag Care Spec Pharm; 2024 Feb; 30(2):163-174. PubMed ID: 38308627
[TBL] [Abstract][Full Text] [Related]
26. Real-life prevalence of progressive fibrosing interstitial lung diseases.
Gagliardi M; Berg DV; Heylen CE; Koenig S; Hoton D; Tamirou F; Pieters T; Ghaye B; Froidure A
Sci Rep; 2021 Dec; 11(1):23988. PubMed ID: 34907290
[TBL] [Abstract][Full Text] [Related]
27. Extracellular Heat Shock Proteins as Therapeutic Targets and Biomarkers in Fibrosing Interstitial Lung Diseases.
Tanguy J; Pommerolle L; Garrido C; Kolb M; Bonniaud P; Goirand F; Bellaye PS
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502225
[TBL] [Abstract][Full Text] [Related]
28. [Epidemiology of fibrosing interstitial lung diseases in the department of Haute Garonne].
Villeneuve T; Prévot G; Lintz F; Mourin G; Ferry G; Bousquet E; Perelroizen H; Boghanim T; Faviez G; Noël-Savina E; Collot S; Le Borgne A; Didier A
Rev Mal Respir; 2021 Dec; 38(10):972-979. PubMed ID: 34629221
[TBL] [Abstract][Full Text] [Related]
29. Healthcare Resources Utilization and Costs of Patients with Non-IPF Progressive Fibrosing Interstitial Lung Disease Based on Insurance Claims in the USA.
Olson AL; Maher TM; Acciai V; Mounir B; Quaresma M; Zouad-Lejour L; Wells CD; De Loureiro L
Adv Ther; 2020 Jul; 37(7):3292-3298. PubMed ID: 32451950
[TBL] [Abstract][Full Text] [Related]
30. CT predictors of outcomes in patients with connective tissue disease and progressive lung fibrosis.
Shou AY; Salvatore MM
Clin Imaging; 2023 Feb; 94():42-49. PubMed ID: 36493681
[TBL] [Abstract][Full Text] [Related]
31. Pictorial Review of Fibrotic Interstitial Lung Disease on High-Resolution CT Scan and Updated Classification.
Brixey AG; Oh AS; Alsamarraie A; Chung JH
Chest; 2024 Apr; 165(4):908-923. PubMed ID: 38056824
[TBL] [Abstract][Full Text] [Related]
32. Progressive fibrotic interstitial lung disease.
Pereira CAC; Cordero S; Resende AC
J Bras Pneumol; 2023; 49(5):e20230098. PubMed ID: 37610955
[TBL] [Abstract][Full Text] [Related]
33. Clubbing in patients with fibrotic interstitial lung diseases.
van Manen MJG; Vermeer LC; Moor CC; Vrijenhoeff R; Grutters JC; Veltkamp M; Wijsenbeek MS
Respir Med; 2017 Nov; 132():226-231. PubMed ID: 29229102
[TBL] [Abstract][Full Text] [Related]
34. A cluster-based analysis evaluating the impact of comorbidities in fibrotic interstitial lung disease.
Wong AW; Lee TY; Johannson KA; Assayag D; Morisset J; Fell CD; Fisher JH; Shapera S; Gershon AS; Cox G; Halayko AJ; Hambly N; Manganas H; Sadatsafavi M; Wilcox PG; To T; Marcoux V; Khalil N; Kolb M; Ryerson CJ
Respir Res; 2020 Dec; 21(1):322. PubMed ID: 33287805
[TBL] [Abstract][Full Text] [Related]
35. Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial.
Matteson EL; Kelly C; Distler JHW; Hoffmann-Vold AM; Seibold JR; Mittoo S; Dellaripa PF; Aringer M; Pope J; Distler O; James A; Schlenker-Herceg R; Stowasser S; Quaresma M; Flaherty KR;
Arthritis Rheumatol; 2022 Jun; 74(6):1039-1047. PubMed ID: 35199968
[TBL] [Abstract][Full Text] [Related]
36. The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype.
Olson AL; Gifford AH; Inase N; Fernández Pérez ER; Suda T
Eur Respir Rev; 2018 Dec; 27(150):. PubMed ID: 30578336
[TBL] [Abstract][Full Text] [Related]
37. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
[TBL] [Abstract][Full Text] [Related]
38. Management of Fibrosing Interstitial Lung Diseases.
Maher TM; Wuyts W
Adv Ther; 2019 Jul; 36(7):1518-1531. PubMed ID: 31119691
[TBL] [Abstract][Full Text] [Related]
39. The Role of Lung Microbiome in Fibrotic Interstitial Lung Disease-A Systematic Review.
Puiu R; Motoc NS; Lucaciu S; Ruta MV; Rajnoveanu RM; Todea DA; Man MA
Biomolecules; 2024 Feb; 14(3):. PubMed ID: 38540667
[TBL] [Abstract][Full Text] [Related]
40. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management.
Wijsenbeek M; Kreuter M; Olson A; Fischer A; Bendstrup E; Wells CD; Denton CP; Mounir B; Zouad-Lejour L; Quaresma M; Cottin V
Curr Med Res Opin; 2019 Nov; 35(11):2015-2024. PubMed ID: 31328965
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
